Trio of genes plays role in breast ca mets to brain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Cell surface coating may play a major role in the spread of breast cancer to the brain, according to a study out of Memorial Sloan-Kettering Cancer Center in New York. Three genes-COX2, HB-EGF, and ST6GALNAC5-have been found to mediate the metastasis of breast cancer to the brain, reported lead author Joan Massagué, PhD, and colleagues (Nature online, May 6, 2009)

Cell surface coating may play a major role in the spread of breast cancer to the brain, according to a study out of Memorial Sloan-Kettering Cancer Center in New York. Three genes-COX2, HB-EGF, and ST6GALNAC5-have been found to mediate the metastasis of breast cancer to the brain, reported lead author Joan Massagu, PhD, and colleagues (Nature online, May 6, 2009).

COX2 and HB-EGF induce cancer cell mobility and invasiveness, while ST6GALNAC5 provide cells with the capability of exiting the blood circulation and passing through the blood-brain barrier, they explained. The researchers isolated cancer cells that preferentially targeted the brain from patients with advanced disease.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content